Screening Guidelines: Ovarian Cancer Screening References

  1. Cancer Facts & Figures, 2008. American Cancer Society.
  2. 1. Ries LAG, Harkins D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD.

  3. Brinton, LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril. 2004; 82:405-14. [PubMed Abstract]
  4. Rossing MA,Tang MC, Flagg EW, Weiss LK. Wicklund KG. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004 Dec 1;160(11):1070-8. [PubMed Abstract]
  5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288:321-33. [PubMed Abstract]
  6. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002; 155:217-24. [PubMed Abstract]
  7. Gertig DM, Hunter DJ, Cramer DW, et al. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst. 2000; 92:249-52. [PubMed Abstract]
  8. Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer. 2001; 11:423-9. [PubMed Abstract]
  9. Kjaer SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH. Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65,000 sterilized women. Int J Epidemiol. 2004; 33:596-602. [PubMed Abstract]
  10. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2 and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998; 178: 670-677. [PubMed Abstract]
  11. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68: 700-710. [PubMed Abstract]
  12. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104:2807-16. [PubMed Abstract]
  13. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997; 336:1401-8. [PubMed Abstract]
  14. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62:676-89. [PubMed Abstract]
  15. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72:1117-30. [PubMed Abstract]
  16. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997; 6:105-10. [PubMed Abstract]
  17. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999; 81:214-8. [PubMed Abstract]
  18. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol. 1992; 80:700-7. [PubMed Abstract]
  19. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 1998; 105:493-9. [PubMed Abstract]
  20. Bergfeldt K, Rydh B, Granath F, et al. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet. 2002; 360:891-4. [PubMed Abstract]
  21. Kauff ND, Mitra M, Robson ME, et al. Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Negative Hereditary Breast Cancer Families. Journal of the National Cancer Institute. 2005; 97:1382-4. [PubMed Abstract]
  22. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353:1207-10. [PubMed Abstract]
  23. Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health Technology Assessment. 1998; 2:1-84. [PubMed Abstract]
  24. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000; 77:350-6. [PubMed Abstract]
  25. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005; 193:1630-9. [PubMed Abstract]
  26. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359:572-7. [PubMed Abstract]
  27. American Cancer Society. Ovarian Cancer: Can Ovarian Cancer Be Found Early? Atlanta, GA: American Cancer Society 2006.
  28. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: The role of the generalist obstetrician in the early detection of ovarian cancer. Obstet Gynecol 2002; 100:1413-6. [PubMed Abstract]
  29. US Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. Ann Fam Med. 2004; 2:260-2. [PubMed Abstract]
  30. National Cancer Institute. Ovarian Cancer (PDQ®): Prevention Health Professional Version. Bethesda, MD: National Cancer Institute, 2006.
  31. The National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. Clinical Practice Guidelines in Oncology. Version 1. 2006. [PubMed Abstract]